Aspen Neuroscience, Inc S-1/A, filed Oct 26, 2026

Aspen Neuroscience, Inc. (ASPE)

Aspen Neuroscience, Inc. proposes an initial public offering of 9,375,000 common shares at $15.00 to $17.00 per share and plans to list under “ASPE” on Nasdaq Global Select Market. Its sasineprocel ASPIRO trial had dosed 15 patients by August 18, 2026. AI summary